Modifiable Risk Factors for Subsequent Lethal Prostate Cancer Among Men with an Initially Negative Prostate Biopsy

Overview

Journal Br J Cancer

Specialty Oncology

Date 2023 Oct 29

PMID 37898724

Authors

Xiaoshuang Feng

Yiwen Zhang

J Bailey Vaselkiv

Ruifeng Li

Paul L Nguyen

Kathryn L Penney

Edward L Giovannucci

Lorelei A Mucci

Konrad H Stopsack

Affiliations

Soon will be listed here.

Abstract

Background: Previously suggested modifiable risk factors for prostate cancer could have resulted from detection bias because diagnosis requires a biopsy. We investigated modifiable risk factors for a subsequent cancer diagnosis among men with an initially negative prostate biopsy.

Methods: In total, 10,396 participants of the Health Professionals Follow-up Study with an initial negative prostate biopsy after 1994 were followed for incident prostate cancer until 2017. Potential risk factors were based on previous studies in the general population. Outcomes included localised, advanced, and lethal prostate cancer.

Results: With 1851 prostate cancer cases (168 lethal) diagnosed over 23 years of follow-up, the 20-year risk of any prostate cancer diagnosis was 18.5% (95% CI: 17.7-19.3). Higher BMI and lower alcohol intake tended to be associated with lower rates of localised disease. Coffee, lycopene intake and statin use tended to be associated with lower rates of lethal prostate cancer. Results for other risk factors were less precise but compatible with and of similar direction as for men in the overall cohort.

Conclusions: Risk factors for future prostate cancer among men with a negative biopsy were generally consistent with those for the general population, supporting their validity given reduced detection bias, and could be actionable, if confirmed.

References

Gann P, Fought A, Deaton R, Catalona W, Vonesh E . Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach. J Clin Oncol. 2010; 28(10):1714-20. PMC: 2849765. DOI: 10.1200/JCO.2008.20.3422. View

Wilson K, Shui I, Mucci L, Giovannucci E . Calcium and phosphorus intake and prostate cancer risk: a 24-y follow-up study. Am J Clin Nutr. 2014; 101(1):173-83. PMC: 4266887. DOI: 10.3945/ajcn.114.088716. View

Bylsma L, Alexander D . A review and meta-analysis of prospective studies of red and processed meat, meat cooking methods, heme iron, heterocyclic amines and prostate cancer. Nutr J. 2015; 14:125. PMC: 4687294. DOI: 10.1186/s12937-015-0111-3. View

Moller E, Wilson K, Batista J, Mucci L, Balter K, Giovannucci E . Body size across the life course and prostate cancer in the Health Professionals Follow-up Study. Int J Cancer. 2015; 138(4):853-65. PMC: 5042346. DOI: 10.1002/ijc.29842. View

Pierre-Victor D, Parnes H, Andriole G, Pinsky P . Prostate Cancer Incidence and Mortality Following a Negative Biopsy in a Population Undergoing PSA Screening. Urology. 2021; 155:62-69. DOI: 10.1016/j.urology.2021.05.060. View

Huncharek M, Haddock K, Reid R, Kupelnick B . Smoking as a risk factor for prostate cancer: a meta-analysis of 24 prospective cohort studies. Am J Public Health. 2009; 100(4):693-701. PMC: 2836346. DOI: 10.2105/AJPH.2008.150508. View

Sauer C, Myran D, Costentin C, Zwisler G, Safder T, Papatheodorou S . Effect of long term aspirin use on the incidence of prostate cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2018; 132:66-75. DOI: 10.1016/j.critrevonc.2018.09.013. View

Hong S, Khil H, Lee D, Keum N, Giovannucci E . Alcohol Consumption and the Risk of Prostate Cancer: A Dose-Response Meta-Analysis. Nutrients. 2020; 12(8). PMC: 7468718. DOI: 10.3390/nu12082188. View

Al-Azab R, Toi A, Lockwood G, Kulkarni G, Fleshner N . Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL. Urology. 2007; 69(1):103-7. DOI: 10.1016/j.urology.2006.09.041. View

10.

Klemann N, Roder M, Helgstrand J, Brasso K, Toft B, Vainer B . Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study. Lancet Oncol. 2017; 18(2):221-229. DOI: 10.1016/S1470-2045(17)30025-6. View

11.

Dhillon P, Kenfield S, Stampfer M, Giovannucci E . Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006. Int J Cancer. 2010; 128(10):2444-52. PMC: 3445018. DOI: 10.1002/ijc.25811. View

12.

Sutcliffe S, Giovannucci E, Leitzmann M, Rimm E, Stampfer M, Willett W . A prospective cohort study of red wine consumption and risk of prostate cancer. Int J Cancer. 2007; 120(7):1529-35. DOI: 10.1002/ijc.22498. View

13.

Pernar C, Chomistek A, Barnett J, Ivey K, Al-Shaar L, Roberts S . Validity and Relative Validity of Alternative Methods of Assessing Physical Activity in Epidemiologic Studies: Findings From the Men's Lifestyle Validation Study. Am J Epidemiol. 2022; 191(7):1307-1322. PMC: 9393066. DOI: 10.1093/aje/kwac051. View

14.

Wallner L, Morgenstern H, McGree M, Jacobson D, St Sauver J, Jacobsen S . The effects of body mass index on changes in prostate-specific antigen levels and prostate volume over 15 years of follow-up: implications for prostate cancer detection. Cancer Epidemiol Biomarkers Prev. 2011; 20(3):501-8. PMC: 3051000. DOI: 10.1158/1055-9965.EPI-10-1006. View

15.

Cuzick J, Thorat M, Andriole G, Brawley O, Brown P, Culig Z . Prevention and early detection of prostate cancer. Lancet Oncol. 2014; 15(11):e484-92. PMC: 4203149. DOI: 10.1016/S1470-2045(14)70211-6. View

16.

Jahn J, Giovannucci E, Stampfer M . The high prevalence of undiagnosed prostate cancer at autopsy: implications for epidemiology and treatment of prostate cancer in the Prostate-specific Antigen-era. Int J Cancer. 2015; 137(12):2795-802. PMC: 4485977. DOI: 10.1002/ijc.29408. View

17.

Graff R, Pettersson A, Lis R, Ahearn T, Markt S, Wilson K . Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. Am J Clin Nutr. 2016; 103(3):851-60. PMC: 4763492. DOI: 10.3945/ajcn.115.118703. View

18.

Giovannucci E, Liu Y, Platz E, Stampfer M, Willett W . Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer. 2007; 121(7):1571-8. PMC: 2430098. DOI: 10.1002/ijc.22788. View

19.

Lee K, Seong H, Kim G, Jeong G, Kim J, Park H . Consumption of Fish and ω-3 Fatty Acids and Cancer Risk: An Umbrella Review of Meta-Analyses of Observational Studies. Adv Nutr. 2020; 11(5):1134-1149. PMC: 7490175. DOI: 10.1093/advances/nmaa055. View

20.

Graff R, Ahearn T, Pettersson A, Ebot E, Gerke T, Penney K . Height, Obesity, and the Risk of -Defined Prostate Cancer. Cancer Epidemiol Biomarkers Prev. 2017; 27(2):193-200. PMC: 5809280. DOI: 10.1158/1055-9965.EPI-17-0547. View